Neurocrine Biosciences

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The firm's product includes INGREZZA. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Neurocrine Biosciences reports strong Q4 performance and eyes growth

Neurocrine Biosciences delivered strong performance in Q4 2022, with robust INGREZZA sales and a positive outlook for 2023, supported by significant investments in SG&A and R&D.
The company's focus on expanding into long-term care, advancing pipeline assets, and collaborations for innovative treatments positions it well for growth and addressing unmet needs.
While facing challenges in managing increased spending and market dynamics, Neurocrine remains optimistic about opportunities in expanding treatment reach, market penetration, and advancing clinical programs.

Neurocrine Biosciences reports strong Q1 performance and eyes international expansion

Neurocrine Biosciences had a strong Q1 performance with record sales, upcoming milestones, and disciplined expense management.
The company faces challenges in certain therapeutic categories but is optimistic about addressing unmet needs and expanding internationally.
Opportunities lie in innovative science, market positioning, and portfolio expansion, positioning Neurocrine for future growth.
Addressing concerns around drug interactions, dosing strategies, and trial risks will be crucial for maintaining clinical success and patient safety.

Neurocrine Biosciences excels in Q2, eyes growth opportunities ahead

Neurocrine Biosciences shows strong financial performance and growth prospects.
Focus on INGREZZA's persistency and pipeline advancements drives optimism.
Challenges include market dynamics and clinical trial complexities.
Opportunities lie in new indications, long-term care expansion, and telemedicine.

Neurocrine Biosciences excels in Q3, eyes growth in LTC segment

Neurocrine Biosciences delivered a strong Q3 performance with robust sales, positive regulatory developments, and promising pipeline advancements.
The company's focus on expanding indications, exploring combination therapies, and addressing market opportunities positions it for future growth.
While facing challenges in market evaluation and competition, Neurocrine Biosciences has opportunities to leverage its strengths and drive innovation.
Investors can look forward to upcoming events like the Analyst Day and R&D Day for deeper insights into the company's strategic direction and growth potential.

Neurocrine Biosciences excels in 2023, eyes Crinecerfont launch success

Neurocrine Biosciences had a strong 2023 with notable achievements in sales growth and pipeline advancements. While facing challenges in market dynamics and pricing negotiations, the company is well-positioned to leverage opportunities in upcoming launches and strategic growth initiatives.

Neurocrine Biosciences excels in Q1 with strong sales and pipeline advancements

Neurocrine Biosciences delivered a strong performance in Q1 2024, driven by robust INGREZZA sales, promising Phase II results for NBI-845, and advancements in Crinecerfont development.
The company's strengths lie in its diverse pipeline, financial stability, and strategic focus on chronic therapy and tolerability, positioning it for future growth and innovation.
While facing challenges in dosing optimization and revenue management, Neurocrine has opportunities to leverage its pipeline, explore new treatments, and differentiate its offerings in the market.

Neurocrine Biosciences excels in Q3, poised for growth ahead

Neurocrine Biosciences showcased robust performance in Q3, with strong INGREZZA sales and pipeline success, positioning for future growth.
The company's strengths lie in its expanded sales team, leadership quality, and commitment to innovation and value creation for shareholders.
Challenges include potential payer reimbursement issues, FDA interactions for Phase III strategy, and competitive pressures in the market.
Opportunities abound with upcoming regulatory approvals, pipeline advancements, and targeted commercial strategies for new product launches.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.

SAN DIEGO, July 8, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that Kyle Gano, Chief Business Development and Strategy Officer, will participate in a neuropsychology-focused panel discussion at the William Blair Biotech Focus Conference at 12:00 p.m. Eastern Time on Thursday July 15, 2021.

Neurocrine Biosciences to Participate at the William Blair Biotech Focus Conference

Sarepta Therapeutics

Vertex, Inc.

Our theme of Out Of Favor Health Care Stocks includes healthcare and pharma names that are seeing a disconnect between their financial performance and stock price returns. Specifically, the theme filters for healthcare companies that have grown revenue by at least 50% over the last three years.

Sarepta, Vertex, Neurocrine: There's Deep Value In These Beaten Down Healthcare Stocks

Activision Blizzard

Equinix

FedEx

Union Pacific

With the second quarter of 2021 all but over and the latter half of 2021 right around the corner, many of the top companies we follow on Wall Street are making some changes to their lists of high-conviction stock picks for clients.

BofA Securities Makes Big Summer Changes to US 1 List of Top Stock Picks

Annovis Bio

Arvinas Inc

Avadel Pharma

Anavex Life Sciences

Biohaven Pharmaceutical Hld

Denali Therapeutics

Intra-Cellular Therapies

Karuna Therapeutics Inc

Prothena

SAGE Therapeutics

Cassava Sciences Inc

Supernus Pharmaceuticals

Healthcare faces an important decision as the Supreme Court decides on the Affordable Care Act. Biotechs face an important FDA decision on approval of an Alzheimer's treatment.

Healthcare And Biotech Stocks Face Important Decisions, Remain A Promising Investment

SAN DIEGO, June 1, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Goldman Sachs 42nd Annual Global Healthcare Conference at 1:20 p.m. Eastern Time on Tuesday, June 8, 2021.

Neurocrine Biosciences to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference

Neurocrine once again posted disappointing Ingrezza sales, and while the post-pandemic reopening should help, it likely won't be an immediate recovery. Management is advancing a broad pipeline of high-risk/high-reward candidates into Phase II studies for a range of movement and psychiatric disorders.

Neurocrine Biosciences: Pandemic Pressures And Few Pipeline Catalysts Continue To Weigh On NBIX

SAN DIEGO, May 11, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the 2021 RBC Capital Markets Healthcare Conference at 10:55 a.m. Eastern Time on Tuesday May 18, 2021.

Neurocrine Biosciences to Present at the 2021 RBC Global Healthcare Conference

Neurocrine Biosciences, Inc. (NBIX) CEO Kevin Gorman on Q1 2021 Results - Earnings Call Transcript

Neurocrine (NBIX) delivered earnings and revenue surprises of -29.79% and -4.52%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Neurocrine Biosciences (NBIX) Q1 Earnings and Revenues Miss Estimates

SAN DIEGO, May 5, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the first quarter ended March 31, 2021 and provided revised full-year 2021 financial expense guidance. "Our first quarter results reflect a lower than normal refill rate per patient due to the typical seasonal payor dynamics for INGREZZA that were exacerbated by COVID.

Neurocrine Biosciences Reports First Quarter 2021 Financial Results

SAN DIEGO, May 4, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Bank of America 2021 Healthcare Conference at 11:00 a.m. Eastern Time on Tuesday May 11, 2021.

Neurocrine Biosciences to Present at the Bank of America 2021 Healthcare Conference

SAN DIEGO, May 3, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its support of Mental Health Month and commitment to raising awareness of and supporting people living with tardive dyskinesia (TD). Some people living with a mental health condition may also experience TD, an involuntary movement disorder that may develop after a few months of taking certain medications to treat bipolar disorder, depression and schizophrenia.1-3 The uncontrollable movements of TD, which can affect the face, torso and/or other body parts, may be disruptive to people's lives due to the symptoms and impact on their physical, emotional and social well-being.1,2,4 To help raise awareness of TD, the mental health advocacy community and states across the country are recognizing the first full week of May (2-8) as Tardive Dyskinesia Awareness Week for the fourth year in a row.

Neurocrine Biosciences Supports Mental Health Month and Tardive Dyskinesia Awareness Week

SAN DIEGO, April 16, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the appointment of Johanna Mercier to its Board of Directors. Ms. Mercier is the Chief Commercial Officer of Gilead Sciences, with responsibility for the global commercialization of Gilead's medicines.

Neurocrine Biosciences Announces Appointment of Johanna Mercier to Board of Directors

SAN DIEGO, April 14, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it will report first quarter 2021 financial results after the Nasdaq market closes on Wednesday, May 5, 2021. Neurocrine will then host a conference call and webcast to discuss its financial results and provide a company update that day at 1:30 p.m.

Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2021 Financial Results

SAN DIEGO, April 8, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present data from its movement disorders and epilepsy programs at the American Academy of Neurology's (AAN) 73rd Annual Meeting being held virtually from April 17–22, 2021. Key highlights include: Analysis from the KINECT 4 Phase III open-label study that demonstrated the effect of INGREZZA® (valbenazine) capsules on the overall severity of abnormal movements in adult patients living with tardive dyskinesia based on item 8 of the abnormal involuntary movement scale (AIMS) Phase III post-hoc sub-group data analysis that showed long-term use (one-year duration) of ONGENTYS® (opicapone) capsules in patients with Parkinson's disease with motor fluctuations reduced "on" time with troublesome dyskinesia and increased "on" time without troublesome dyskinesia New real-world data from EMPATHY, a retrospective medical chart review, highlight the need to simplify treatment regimens for patients with Parkinson's disease to manage motor fluctuations Results of an online caregiver survey include data on the relationship between genetic variants and disease characteristics in patients with SCN8A developmental epileptic encephalopathy (SCN8A-DEE) and SCN8A-related epilepsy Data from the Enroll-HD registry, a worldwide observational study, showed that the majority of patients with manifest Huntington disease have chorea, yet the majority of those with chorea were not prescribed medication to treat the condition.

Neurocrine Biosciences to Present Data from its Neurology Portfolio at the American Academy of Neurology's 73rd 2021 Virtual Meeting

Neurocrine (NBIX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Strength Seen in Neurocrine (NBIX): Can Its 11.1% Jump Turn into More Strength?

SAN DIEGO, March 25, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Stifel 3rd Annual CNS Day at 12:30 p.m. Eastern Time on Thursday Apr. 1, 2021.

Neurocrine Biosciences to Present at Stifel 3rd Annual CNS Day

The stock is being added to a mid-cap index.

Why Neurocrine Biosciences Stock Jumped Today

The stock price of Neurocrine Biosciences, Inc. (NASDAQ: NBIX) has increased by over 13% during intraday trading. This is why it happened.

NBIX Stock Price Increased Over 13% Intraday: Why It Happened

Owens-Illinois

NEW YORK, March 24, 2021 /PRNewswire/ -- Neurocrine Biosciences Inc. (NASD:NBIX) will replace O-I Glass Inc. (NYSE:OI) in the S&P MidCap 400, and O-I Glass will replace HMS Holdings Corp (NASD:HMSY) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, March 30. Veritas Capital is acquiring HMS Holding in a deal expected to be completed soon pending final conditions.

Neurocrine Biosciences Set to Join S&P MidCap 400; O-I Glass to Join S&P SmallCap 600

SAN DIEGO, March 20, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present additional positive data from its Phase II CAHlibrate study of crinecerfont, an investigational, oral, non-steroidal corticotropin-releasing factor type 1 (CRF1) receptor antagonist for the potential treatment of classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21-OHD), at ENDO 2021, the Endocrine Society's annual meeting, on March 20–23, 2021. These new analyses, based on data from seven male subjects with classic CAH receiving crinecerfont, demonstrate dose-dependent decreases in androstenedione (A4), a key marker of CAH control and precursor to testosterone, with similar dose-dependent decreases in the A4 to testosterone ratio.

Neurocrine Biosciences to Present New Data Analyses for Crinecerfont in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2021

Blackrock Inc

Citigroup

Goldman Sachs

Medtronic

Just like that, we are less than two weeks from the end of the first quarter. While it has been a very positive one for investors, the rise in interest rates has brought in much higher volatility and has really pressured technology stocks.

5 Analyst Favorite Stocks to Buy for Q2 That Could Be Huge Winners

Centene

Out Of Favor Health Care Stocks includes healthcare and pharma names that have done reasonably well financially in recent years, although their stock prices have lagged, due to Covid-19 related disruptions in the healthcare industry or due to some setbacks in their development pipelines.

Centene, Neurocrine, Sarepta: Will These Out Of Favor Healthcare Stocks Outperform?

A few months back we discussed why Neurocrine Biosciences stock, a biotech company that develops treatments for neurological and endocrine-related diseases and disorders, looks oversold at $90 levels. Between mid-December 2020 to mid-February 2021, NBIX stock rallied over 30% from $90 to $120.

The Sell-off In Neurocrine Stock Post Luvadaxistat Failure Is Unwarranted

SAN DIEGO, March 9, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Oppenheimer 31st Annual Healthcare Conference at 4:30 p.m. Eastern Time on Tuesday Mar. 16, 2021.

News for Neurocrine Biosciences Stock (NBIX)